MarketSmith India has initiated coverage on Anthem Biosciences and Shivalik Bimetal Controls, highlighting growth in pharmaceutical manufacturing and e-mobility. While these niche sectors show promise, investors should balance the potential against risks like high client concentration and raw material price volatility.
MarketSmith India has released research coverage on Anthem Biosciences and Shivalik Bimetal Controls, pointing to structural growth trends in niche manufacturing sectors. The update comes as the broader Indian market faces a period of volatility, with the Nifty 50 index seeing a minor decline of 0.52% on Wednesday. Despite the market pressure, the focus on these two companies highlights investor interest in specialized businesses that operate within the pharmaceutical and electric vehicle ecosystems.
Anthem Biosciences and the CRDMO Shift
Anthem Biosciences has been under the spotlight due to its operations in the Contract Research, Development and Manufacturing Organization (CRDMO) sector. Trading around the ₹923 level, the company is scaling its fermentation capacity to handle demand for GLP-1 APIs and peptides. A key factor driving the positive outlook is the U.S. Biosecure Act, which is encouraging global pharmaceutical companies to shift their supply chains away from China, potentially benefiting Indian manufacturers.
However, investors should consider the operational risks. The company has a notable client concentration, with its top five customers contributing over 70% of its total revenue. This reliance means that the loss or reduction in orders from any major client could impact the company’s revenue stability. While the company maintains a net cash position, successful execution of its capacity expansion projects remains a critical monitorable for long-term growth.
Shivalik Bimetal Controls in E-Mobility
Shivalik Bimetal Controls, trading near ₹1,053, is being monitored for its role in the electric vehicle (EV) and industrial smart metering sectors. The company’s performance has been robust, highlighted by a 44.9% rise in consolidated net profit for the quarter ended June 2026. This growth is largely driven by its specialized shunt resistors and bimetal products, which are essential components in EV infrastructure.
Despite the growth, the business faces specific pressures. The company is heavily dependent on major OEMs and distributors like Vishay. Furthermore, because its manufacturing process involves metals like copper and nickel, the company’s profit margins are directly sensitive to fluctuations in global commodity prices. Investors should track how the company manages these raw material costs, as any volatility could pressure operating margins.
Market Context and Next Steps
Although the major indices like Nifty 50 saw a dip on Wednesday, the overall market breadth remained resilient, with many stocks advancing. This suggests that the current corrective phase is not a widespread sell-off, but rather a sectoral adjustment. For shareholders of both Anthem Biosciences and Shivalik Bimetal Controls, the next phase will depend on their ability to sustain margin performance and execute project timelines. Investors should monitor quarterly updates for signs of client diversification and commodity cost management, which will be critical in confirming whether these companies can maintain their current growth trajectory.